Russian President Vladimir Putin meeting with the CEO of the Russian Direct Investment Fund Kirill Dmitriev
Russian Ministry of Health approves the first COVID-19 drug Avifavir produced by JV of RDIF and ChemRar Moscow,
May 30, 2020 –
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group
today announce that Avifavir has received a temporary registration certificate from the Ministry of Health of the Russian Federation.
Avifavir
is Russia’s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials.
Online press conference with details about Avifavir
will be held on June 1 at 10:00 Moscow time. Further information about the conference/media can be found at
Avifavir,
which disrupts the reproduction mechanisms of coronavirus,
is the first Russian direct antiviral drug that has proven effective in clinical trials.
The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.
The intermediate data of Avifavir clinical trials confirm its high efficacy against COVID-19.
The final stage of Avifavir clinical trials involving 330 patients, approved by the Russian Ministry of Health on May 21, 2020, is ongoing.
The drug proved to be highly effective during the clinical trials involving
- I.M. Sechenov First Moscow State Medical University,
- Lomonosov Moscow State University and
- other medical and academic institutions.
Kirill Dmitriev,
CEO of the Russian Direct Investment Fund, said:
Afivavir is not only the first antiviral drug registered against coronavirus in Russia,
but it is also perhaps the most promising anti-COVID-19 drug in the world.
It was developed and tested in clinical trials in Russia in unprecedentedly short period of time enabling Afivavir to become the first registered drug based on Favipiravir in the world.
***
Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011
RDIF has established joint strategic partnerships with leading international co-investors from more than 15 countries that total more than $40 bn.
RDIF takes active steps to counteract COVID-19:
RDIF and partners have launched the production of the unique Russian-Japanese EMG diagnostic system,
which generates results in 30 minutes with a very high accuracy in both stationary and unmatched portable mini-laboratories.
The Japan Bank for International Cooperation has joined the project through the Russia-Japan Investment Fund;
RDIF and the ChemRar Group
have produced the first batch of Favipiravir, a drug that has proven effective in the treatment of infected patients in China and in clinical trials in Russia.
Preparations are currently underway for the mass production of the drug;
RDIF has launched a project to diagnose and detect pneumonia, including that caused by coronavirus,
using CT scans combined with
the Russian-UAE artificial intelligence (AI) technology developed jointly by Group 42 (G42), RDIF and Medscan Group;
ChemRar Group
celebrates its 30th anniversary in 2020. Throughout its history, the company has maintained and improved the achievements and quality of its medical chemistry
and has saved its personnel reserve of world-class employees and scientists, thanks to which ChemRar is one of the global leaders in the industry today.
https://rdif.ru/Eng_fullNews/5220/
Coronavirus, Covid-19 Drugs, Vaccines: Russia Approves Avifavir